KR100344479B1 - 카바페넴항생물질을안정화시키는방법 - Google Patents

카바페넴항생물질을안정화시키는방법 Download PDF

Info

Publication number
KR100344479B1
KR100344479B1 KR1019980700717A KR19980700717A KR100344479B1 KR 100344479 B1 KR100344479 B1 KR 100344479B1 KR 1019980700717 A KR1019980700717 A KR 1019980700717A KR 19980700717 A KR19980700717 A KR 19980700717A KR 100344479 B1 KR100344479 B1 KR 100344479B1
Authority
KR
South Korea
Prior art keywords
formula
compound
pharmaceutically acceptable
acceptable salt
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1019980700717A
Other languages
English (en)
Korean (ko)
Other versions
KR19990036052A (enExample
Inventor
제프리 에이. 짐머만
존 엠. 윌리암스
폴 에이. 버그퀴스트
리사 엠. 디미첼
데이비드 씨. 듀보스트
마이클 제이. 카우프만
다니엘 알. 시들러
윌리암 에이. 헌크
Original Assignee
머크 앤드 캄파니 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9612668.5A external-priority patent/GB9612668D0/en
Application filed by 머크 앤드 캄파니 인코포레이티드 filed Critical 머크 앤드 캄파니 인코포레이티드
Priority to KR10-2001-7008925A priority Critical patent/KR100403497B1/ko
Publication of KR19990036052A publication Critical patent/KR19990036052A/ko
Application granted granted Critical
Publication of KR100344479B1 publication Critical patent/KR100344479B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D499/88—Compounds with a double bond between positions 2 and 3 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D499/887—Compounds with a double bond between positions 2 and 3 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with a hetero atom or a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
    • C07D477/16—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
    • C07D477/20—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1019980700717A 1996-05-28 1997-05-23 카바페넴항생물질을안정화시키는방법 Expired - Lifetime KR100344479B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR10-2001-7008925A KR100403497B1 (ko) 1996-05-28 1997-05-23 카바페넴 항생물질

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1851896P 1996-05-28 1996-05-28
GBGB9612668.5A GB9612668D0 (en) 1996-06-18 1996-06-18 Carbapenem antibiotic composition and method of preparation
GB60/018,518 1996-06-18
GB9612668.5 1996-06-18
PCT/US1997/008831 WO1997045430A1 (en) 1996-05-28 1997-05-23 Carbapenem antibiotic, composition and method of preparation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR10-2001-7008925A Division KR100403497B1 (ko) 1996-05-28 1997-05-23 카바페넴 항생물질

Publications (2)

Publication Number Publication Date
KR19990036052A KR19990036052A (enExample) 1999-05-25
KR100344479B1 true KR100344479B1 (ko) 2002-10-31

Family

ID=26309530

Family Applications (2)

Application Number Title Priority Date Filing Date
KR10-2001-7008925A Expired - Lifetime KR100403497B1 (ko) 1996-05-28 1997-05-23 카바페넴 항생물질
KR1019980700717A Expired - Lifetime KR100344479B1 (ko) 1996-05-28 1997-05-23 카바페넴항생물질을안정화시키는방법

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR10-2001-7008925A Expired - Lifetime KR100403497B1 (ko) 1996-05-28 1997-05-23 카바페넴 항생물질

Country Status (33)

Country Link
EP (1) EP0863901B1 (enExample)
JP (2) JPH11509871A (enExample)
KR (2) KR100403497B1 (enExample)
CN (1) CN1067074C (enExample)
AT (1) ATE252584T1 (enExample)
AU (1) AU710102B2 (enExample)
BG (1) BG63821B1 (enExample)
CA (1) CA2227994C (enExample)
CO (1) CO4940412A1 (enExample)
CY (1) CY2437B1 (enExample)
CZ (1) CZ296381B6 (enExample)
DE (1) DE69725696T2 (enExample)
DK (1) DK0863901T3 (enExample)
DZ (1) DZ2242A1 (enExample)
EA (1) EA000534B1 (enExample)
EE (1) EE04678B1 (enExample)
ES (1) ES2208907T3 (enExample)
HR (1) HRP970281B1 (enExample)
HU (1) HU229426B1 (enExample)
ID (1) ID16974A (enExample)
IL (1) IL123078A (enExample)
IS (1) IS2353B (enExample)
MX (1) MX9800808A (enExample)
NO (1) NO323815B1 (enExample)
NZ (1) NZ329649A (enExample)
PL (1) PL188917B1 (enExample)
PT (1) PT863901E (enExample)
RS (1) RS49583B (enExample)
SI (1) SI0863901T1 (enExample)
SK (1) SK284359B6 (enExample)
TR (1) TR199800146T1 (enExample)
TW (1) TW434014B (enExample)
WO (1) WO1997045430A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU725298B2 (en) * 1996-10-28 2000-10-12 Merck & Co., Inc. Stabilized carbapenem antibiotic compositions and method of making
US6180783B1 (en) * 1997-06-16 2001-01-30 Merck & Co., Inc. Stabilized carbapenem intermediates and improved process for carbapenem synthesis
CA2293835C (en) * 1997-06-16 2003-09-16 John M. Williams Stabilized carbapenem intermediates and synthetic use
US6504027B1 (en) 1998-03-02 2003-01-07 Merck & Co., Inc. Decarboxylation process for synthesizing carbapenem antibiotics
WO2001032172A1 (en) * 1999-10-29 2001-05-10 Merck & Co., Inc. Process for formulation of carbapenem antibiotic compositions
AR035728A1 (es) 2001-01-16 2004-07-07 Merck & Co Inc Proceso perfeccionado para la sintesis de carbapenem
CN101357918B (zh) * 2007-06-22 2011-05-18 山东轩竹医药科技有限公司 含有异硫脲基巯基吡咯烷的培南衍生物
CN101367815B (zh) * 2007-06-28 2012-07-04 山东轩竹医药科技有限公司 六元环甲酰胺取代的巯基吡咯烷碳青霉烯化合物
EP2229944A1 (en) 2007-12-12 2010-09-22 Dainippon Sumitomo Pharma Co., Ltd. Preparation composition
CN101550138B (zh) * 2008-04-03 2011-05-18 山东轩竹医药科技有限公司 巯基氮杂环烷酰胺醇取代的培南衍生物
WO2009150630A2 (en) * 2008-06-11 2009-12-17 Ranbaxy Laboratories Limited Process for preparing a carbapenem antibiotic composition
CN102365266B (zh) 2009-03-31 2013-11-06 三菱综合材料株式会社 含氟n-烷基磺酰亚胺化合物及其制造方法、以及离子性化合物的制造方法
WO2010151574A2 (en) 2009-06-25 2010-12-29 Shell Oil Company Water injection systems and methods
WO2012047832A2 (en) 2010-10-07 2012-04-12 Shell Oil Company Process for the production of alcohols from biomass
CN104651539B (zh) 2010-11-05 2018-09-28 国际壳牌研究有限公司 处理生物质以产生可用于生物燃料的材料
WO2012088108A1 (en) 2010-12-20 2012-06-28 Shell Oil Company Process for the production of alcohols from biomass
WO2013090526A1 (en) 2011-12-15 2013-06-20 Shell Oil Company Method of treating byproducts from ethanol production
JP2015523061A (ja) 2012-05-17 2015-08-13 シエル・インターナシヨネイル・リサーチ・マーチヤツピイ・ベー・ウイＳｈｅｌｌ Ｉｎｔｅｒｎａｔｉｏｎａｌｅ Ｒｅｓｅａｒｃｈ Ｍａａｔｓｃｈａｐｐｉｊ Ｂｅｓｌｏｔｅｎｖｅｎｎｏｏｔｓｈａｐ バイオマス材料を処理する方法およびシステム
CN103860485A (zh) * 2012-12-18 2014-06-18 深圳市海滨制药有限公司 一种厄他培南钠冻干制剂及其制备方法
EP3132045A1 (en) 2014-04-17 2017-02-22 Shell Internationale Research Maatschappij B.V. Processes for producing fermentation products
CN106536495A (zh) 2014-08-14 2017-03-22 国际壳牌研究有限公司 从生物质制备糠醛的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993015078A1 (en) * 1992-02-04 1993-08-05 Zeneca Limited Carbapenems containing a carboxy substituted phenyl group, processes for their preparation, intermediates and use as antibiotics

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES525492A0 (es) * 1982-09-10 1985-02-01 Glaxo Group Ltd Un procedimiento para la produccion de un recipiente hermeticamente cerrado que contiene al menos un antibiotico de beta-lactama.
CA2091309A1 (en) * 1992-03-26 1993-09-27 Frederic H. Jung Antibiotic compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993015078A1 (en) * 1992-02-04 1993-08-05 Zeneca Limited Carbapenems containing a carboxy substituted phenyl group, processes for their preparation, intermediates and use as antibiotics

Also Published As

Publication number Publication date
DK0863901T3 (da) 2004-02-16
NO980380D0 (no) 1998-01-28
BG63821B1 (bg) 2003-02-28
PT863901E (pt) 2004-02-27
IS2353B (is) 2008-04-15
IL123078A0 (en) 1998-09-24
CO4940412A1 (es) 2000-07-24
EE04678B1 (et) 2006-08-15
CN1198162A (zh) 1998-11-04
HRP970281A2 (en) 1998-06-30
JP2009084284A (ja) 2009-04-23
EA000534B1 (ru) 1999-10-28
IS4663A (is) 1998-01-27
HUP9901567A3 (en) 2000-03-28
CY2437B1 (en) 2004-11-12
TR199800146T1 (xx) 1998-06-22
PL188917B1 (pl) 2005-05-31
JP5255983B2 (ja) 2013-08-07
HRP970281B1 (en) 2002-04-30
AU710102B2 (en) 1999-09-16
EP0863901A1 (en) 1998-09-16
DE69725696T2 (de) 2004-07-29
HK1016176A1 (en) 1999-10-29
HUP9901567A2 (hu) 1999-09-28
NZ329649A (en) 1998-11-25
AU3077597A (en) 1998-01-05
DE69725696D1 (de) 2003-11-27
ATE252584T1 (de) 2003-11-15
NO980380L (no) 1998-03-16
EA199800180A1 (ru) 1998-08-27
ES2208907T3 (es) 2004-06-16
CN1067074C (zh) 2001-06-13
EE9800022A (et) 1998-08-17
JPH11509871A (ja) 1999-08-31
BG102273A (bg) 1998-09-30
MX9800808A (es) 1998-04-30
SI0863901T1 (en) 2004-04-30
SK284359B6 (sk) 2005-02-04
ID16974A (id) 1997-11-27
KR19990036052A (enExample) 1999-05-25
CZ296381B6 (cs) 2006-03-15
DZ2242A1 (fr) 2002-12-18
IL123078A (en) 2002-03-10
NO323815B1 (no) 2007-07-09
CA2227994A1 (en) 1997-12-04
SK10998A3 (en) 1998-08-05
TW434014B (en) 2001-05-16
RS49583B (sr) 2007-04-10
EP0863901B1 (en) 2003-10-22
PL324746A1 (en) 1998-06-08
CZ25398A3 (cs) 1998-07-15
CA2227994C (en) 2002-06-25
WO1997045430A1 (en) 1997-12-04
KR100403497B1 (ko) 2003-10-30
YU4198A (sh) 1998-12-23
HU229426B1 (en) 2013-12-30

Similar Documents

Publication Publication Date Title
KR100344479B1 (ko) 카바페넴항생물질을안정화시키는방법
JP4689959B2 (ja) セファロスポリン化合物を含む処方物ならびにイヌおよびネコにおける細菌感染の治療におけるその使用
DE69425131T2 (de) Verwendung von clavulansäure und einem antibiotikum zur behandlung von infektionen
EP1142573B1 (en) Pharmaceutical compositions comprising faropenem sodium and a diamineacetate compound for improving gastrointestinal absorption
US5952323A (en) Carbapenem antibiotic
US6242424B1 (en) Moenomycin and its derivatives for the production of pharmaceuticals, and pharmaceuticals containing moenomycin or its derivatives
EP0178911B1 (en) Composition containing a penem or carbapenem antibiotic
US20030109503A1 (en) Pharmaceutical formulations comprising clavulanic acid alone or in combination with other beta-lactam antibiotics
WO2001045667A2 (en) Water-soluble powders for oral solution and use thereof
JP2012502983A (ja) 新規単回単位カルバペネムアミノグリコシド製剤
CA1285226C (en) Compositions containing a 2,4-diamino-pyrimidine and sulphadimidine
BR9702231B1 (pt) composição farmacêutica, composto, e, processo para estabilizar um carbapenem
NZ237931A (en) Treatment of pigs with amoxycillin and clavulanic acid (or salts thereof) for farrowing fever or pneumonia
JP2003146906A (ja) グラム陽性菌感染症の予防または治療のための併用療法剤
JPS6191191A (ja) 抗菌性７β‐複素環式セフエム

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19980126

Patent event code: PA01051R01D

Comment text: International Patent Application

A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19980410

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20000531

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20010316

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20000531

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20010615

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20010316

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20020430

Appeal identifier: 2001101001735

Request date: 20010615

A107 Divisional application of patent
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20010714

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20010714

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20010615

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20000930

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 19980410

Patent event code: PB09011R02I

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20010803

Patent event code: PE09021S01D

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20020430

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20010720

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20020704

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20020705

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20050630

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20060630

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20070702

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20080624

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20090630

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20100630

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20110629

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20120628

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20130628

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20130628

Start annual number: 12

End annual number: 12

FPAY Annual fee payment

Payment date: 20140627

Year of fee payment: 13

PR1001 Payment of annual fee

Payment date: 20140627

Start annual number: 13

End annual number: 13

PR1001 Payment of annual fee

Payment date: 20150630

Start annual number: 14

End annual number: 14

FPAY Annual fee payment

Payment date: 20160629

Year of fee payment: 15

PR1001 Payment of annual fee

Payment date: 20160629

Start annual number: 15

End annual number: 15

EXPY Expiration of term
PC1801 Expiration of term

Termination date: 20171123

Termination category: Expiration of duration